Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03874910
Other study ID # 0115-18-HYMC
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 19, 2019
Est. completion date March 2023

Study information

Verified date March 2019
Source Hillel Yaffe Medical Center
Contact Itzhak Braverman, Doctor (MD)
Phone +972-4-6304549
Email braverman@hy.health.gov.il
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study aims to characterize the effect of OPMD mutation on muscle function. Muscle samples will be received from oculopharyngeal muscular dystrophy (OPMD) patients who undergo cricopharyngeal muscle-cutting surgery, as part of their routine healthcare and treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date March 2023
Est. primary completion date March 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- OPMD patients both male and female.

- OPMD patients between the ages 18-70 years.

- OPMD patients who are referred to the cricopharyngeal muscle-cutting surgery as part of their usual treatment.

Exclusion Criteria:

• OPMD patients not referred to the cricopharyngeal muscle-cutting surgery as part of their usual treatment.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Israel Hillel Yaffe Medical Center Hadera

Sponsors (1)

Lead Sponsor Collaborator
Hillel Yaffe Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of genes that show changes in RNA profile, measured by sequencing. RNA profile analysis of OPMD muscle samples will be compared to unaffected muscle samples using sequencing to identify gene numbers. Data will be collected within four years.
Primary Number of genes that show changes in protein profile, measured by SDS page. Protein profile analysis of OPMD muscle samples will be compared to unaffected muscle samples to identify gene numbers using SDS page. Data will be collected within four years.
See also
  Status Clinical Trial Phase
Completed NCT02877784 - Screening in Oculopharyngeal Muscular Dystrophy
Recruiting NCT06185673 - A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia Phase 1/Phase 2
Enrolling by invitation NCT04009408 - Expiratory Muscle Strength Training (EMST) in Neuromuscular Disorders N/A
Withdrawn NCT04226924 - Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose Phase 2
Recruiting NCT02158156 - Effect of Aerobic Training in Patients With Oculopharyngeal Muscular Dystrophy N/A
Completed NCT02015481 - Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients Phase 2
Withdrawn NCT03161847 - Natural History Study of Oculopharyngeal Muscular Dystrophy